PLK
PLK (Polo-like kinase 1) is a serine/threonine-protein that are implicated in cell cycle, mitosis, cytokinesis and DNA damage etc.
Products for PLK
- Cat.No. Product Name Information
- GC62728 (1E)-CFI-400437 dihydrochloride (1E)-CFI-400437 dihydrochloride is a potent PLK4 (IC50= 0.6 nM) inhibitor and selective against other members of the PLK family (>10 μM). (1E)-CFI-400437 dihydrochloride inhibits Aurora A, Aurora B, KDR and FLT-3 with IC50s of 0.37, 0.21, 0.48, and 0.18 μM, respectively. Antiproliferative activity.
- GC14186 3MB-PP1 polo-like kinase 1 (Plk1) allele inhibitor,ATP-competitive
- GC35216 AAPK-25 AAPK-25 is a potent and selective Aurora/PLK dual inhibitor with anti-tumor activity, which can cause mitotic delay and arrest cells in a prometaphase, reflecting by the biomarker histone H3Ser10 phosphorylation and followed by a surge in apoptosis. AAPK-25 targets Aurora-A, -B, and -C with Kd values ranging from 23-289 nM, as well as PLK-1, -2, and -3 with Kd values ranging from 55-456 nM.
- GC11224 BI6727(Volasertib) BI6727(Volasertib) (BI 6727) is an orally active, highly potent and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with an IC50 of 0.87 nM. BI6727(Volasertib) inhibits PLK2 and PLK3 with IC50s of 5 and 56 nM, respectively. BI6727(Volasertib) induces mitotic arrest and apoptosis. BI6727(Volasertib), a dihydropteridinone derivative, shows marked antitumor activity in multiple cancer models.
- GC32688 Centrinone (LCR-263) Centrinone (LCR-263) (LCR-263) is a selective and reversible inhibitor of polo-like kinase 4 (PLK4) with a Ki of 0.16 nM.
- GC32751 Centrinone-B (LCR-323) Centrinone-B (LCR-323) (LCR-323) is a potent and highly selective PLK4 inhibitor, with a Ki of 0.59 nM.
-
GC13606
CFI-400945
orally available, selective inhibitor of polo-like kinase 4 (PLK4)
- GC35660 CFI-400945 free base
- GC13268 Cyclapolin 9 PLK1 inhibitor
- GC12335 GSK461364 Plk1 inhibitor
- GC49280 GSK579289A A Plk1 inhibitor
- GC11621 GW843682X A reversible polo-like kinase inhibitor
- GC13928 HMN-214 Plk inhibitor,broad-spectrum anti-tumor agent
- GC14857 LFM-A13 BTK-specific tyrosine kinase inhibitor
- GC10163 MLN0905 Potent PLK1 inhibitor
- GC15745 Mps1-IN-2 Mps1 kinase inhibitor
- GC12515 NMS-1286937 NMS-1286937 is a potent, selective and orally available PLK1 inhibitor, with an IC50 of 2 nM.
- GC62174 ON1231320 ON1231320 is a highly specific polo like kinase 2 (PLK2) inhibitor with an IC50 of 0.31 ?M. ON1231320 blocks tumor cell cycle progression in the G2/M phase in mitosis, causing apoptotic cell death. ON1231320, an arylsulfonyl pyrido-pyrimidinone, has antitumor activity.
- GC65189 PLK4-IN-1 PLK4-IN-1 (Example A6) is a PLK4 inhibitor, with an IC50 of ≤ 0.1 μM.
-
GC69718
Plogosertib
Plogosertib (CYC140) is a selective, potent, orally active ATP-competitive PLK1 inhibitor (IC50: 3 nM). Plogosertib is an anti-cancer agent with anti-proliferative activity and can be used for research on various tumors including esophageal cancer, gastric cancer, leukemia, non-small cell lung cancer, ovarian cancer and squamous cell carcinoma.
- GC14735 Poloxime polo-like kinase 1 (PLK) analogue
- GC13543 Poloxin An inhibitor of the Plk1 polo-box domain
-
GC12415
Rigosertib
PI3K/PLK1 inhibitor
- GC14358 Rigosertib (ON-01910,Estybon) Plk1 inhibitor
-
GC13580
Rigosertib sodium
Non-ATP-competitive inhibitor of PLK1
- GC13903 Ro3280 PLK1 inhibitor,potent and highly selective
- GC14644 SBE 13 HCl SBE 13 HCl is a potent and selective Plk1 inhibitor, with an IC50 of 200 pM; SBE 13 HCl poorly inhibits Plk2 (IC50>66μM) or Plk3 (IC50=875nM).
- GC37601 SBE13 SBE13 is a potent and selective Plk1 inhibitor, with an IC50 of 200 pM; SBE13 poorly inhibits Plk2 (IC50>66?μM) or Plk3 (IC50=875?nM).
- GC37725 TAK-960 dihydrochloride TAK-960 dihydrochloride is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC50 of 0.8 nM. TAK-960 dihydrochloride also shows inhibitory activities against PLK2 and PLK3, with IC50s of 16.9 and 50.2 nM, respectively. TAK-960 dihydrochloride inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts.
- GC37726 TAK-960 hydrochloride TAK-960 hydrochloride is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC50 of 0.8 nM. TAK-960 hydrochloride also shows inhibitory activities against PLK2 and PLK3, with IC50s of 16.9 and 50.2 nM, respectively. TAK-960 hydrochloride inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts.
-
GC10773
TAK960
Oral and selective PLK1 inhibitor
- GC16771 TC-S 7005 polo-like kinase 2 (PLK2) inhibitor
- GC12338 Wortmannin Wortmannin is a highly potent direct inhibitor of PI3-kinase specificity originally derived from fungi (1,2).